These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11020957)

  • 1. Autoantibodies and clinical subsets: relevance to scleroderma.
    Maddison PJ
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):684-6. PubMed ID: 11020957
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-collagen IV antibodies in patients with scleroderma and idiopathic Raynaud's phenomenon].
    Gabrielli A; Montroni M; Rupoli S; Caniglia ML; Danieli G
    Recenti Prog Med; 1985 Jan; 76(1):21-2. PubMed ID: 3991970
    [No Abstract]   [Full Text] [Related]  

  • 3. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma).
    Senécal JL; Hénault J; Raymond Y
    J Rheumatol; 2005 Sep; 32(9):1643-9. PubMed ID: 16142854
    [No Abstract]   [Full Text] [Related]  

  • 4. Anticentromere antibodies: clinical and biological significance.
    Fritzler MJ; Ayer LM
    J Rheumatol; 1982; 9(4):489-90. PubMed ID: 6982333
    [No Abstract]   [Full Text] [Related]  

  • 5. [Raynaud's phenomenon and anti-centromeric antibodies].
    Marquet R; Villar MM; Ordi J; de la Figuera M; Vilardell M
    Med Clin (Barc); 1984 Jun; 83(3):129-30. PubMed ID: 6482556
    [No Abstract]   [Full Text] [Related]  

  • 6. [Modification of B-cell precursor frequencies by systemic photochemotherapy (PUVA) in patients with systemic scleroderma].
    Kunzelmann V; Brenke A; Fetscher I; Lukowsky A; Leschik G; Adrian K; Sönnichsen N
    Z Arztl Fortbild (Jena); 1994 Aug; 88(7-8):519-24. PubMed ID: 7856255
    [No Abstract]   [Full Text] [Related]  

  • 7. Early diagnosis of systemic sclerosis.
    Jünger M; Schlez A; Steins A; Zuder D; Hahn M
    Adv Exp Med Biol; 1999; 455():111-3. PubMed ID: 10599331
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies.
    Koenig M; Dieudé M; Senécal JL
    Autoimmun Rev; 2008 Sep; 7(8):588-93. PubMed ID: 18617021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineutrophil cytoplasmic autoantibodies in systemic sclerosis with renal failure.
    Huong DL; Papo T; Gatfosse M; Frances C; Godeau P; Beaufils H
    J Rheumatol; 1995 Apr; 22(4):791-2. PubMed ID: 7791189
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticentromere antibody and Raynaud's phenomenon.
    Czirják L; Schlammadinger J; Szegedi G
    Dermatologica; 1991; 183(1):55. PubMed ID: 1769420
    [No Abstract]   [Full Text] [Related]  

  • 11. [Raynaud disease].
    Pettersson T
    Duodecim; 2005; 121(22):2411-9. PubMed ID: 16457072
    [No Abstract]   [Full Text] [Related]  

  • 12. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease.
    Lyons R; Narain S; Nichols C; Satoh M; Reeves WH
    Ann N Y Acad Sci; 2005 Jun; 1050():217-28. PubMed ID: 16014537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bibliography. Current world literature. Raynaud phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.
    Curr Opin Rheumatol; 2001 Nov; 13(6):B133-6. PubMed ID: 11758498
    [No Abstract]   [Full Text] [Related]  

  • 14. [Relations between Raynaud's disease and scleroderma in the framework of immunological research].
    FARINELLI A; RIPA R; GRANDI L
    Arcisp S Anna Ferrara; 1960; 13(Suppl 6)():1491-517. PubMed ID: 13698198
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of systemic sclerosis.
    Lim IG; Schrieber L
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):953-7. PubMed ID: 12455189
    [No Abstract]   [Full Text] [Related]  

  • 17. [Overlap syndrome].
    Kasukawa R; Kanno T; Takeda I
    Ryoikibetsu Shokogun Shirizu; 2000; (31):427-9. PubMed ID: 11269125
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinico-immunologic shift in systemic scleroderma].
    Drampian FS; Grigorian EG; Aznaurian AV
    Vrach Delo; 1971 Apr; 7():91-4. PubMed ID: 5140143
    [No Abstract]   [Full Text] [Related]  

  • 19. Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis.
    Manetti M; Liakouli V; Fatini C; Cipriani P; Bonino C; Vettori S; Guiducci S; Montecucco C; Abbate R; Valentini G; Matucci-Cerinic M; Giacomelli R; Ibba-Manneschi L
    Ann Rheum Dis; 2009 Mar; 68(3):408-11. PubMed ID: 18930992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of antimitotic spindle-associated antibody assay].
    Obayashi H; Wada T; Fukui I; Nakayama A
    Nihon Rinsho; 1990 Feb; 48 Suppl():599-602. PubMed ID: 2192157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.